Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

LNTH Stock - Lantheus Holdings Stock Trading


home / stock / lnth

LNTH LNTH Quote LNTH Short LNTH News LNTH Articles LNTH Message Board

MWN AI Summary *

Lantheus Holdings Inc. (NASDAQ: LNTH) is a leading biotechnology company focused on pioneering innovations in diagnostic imaging and therapeutics. Founded in 1956 and based in North Billerica, Massachusetts, Lantheus specializes in developing and commercializing proprietary radiopharmaceuticals designed primarily for the diagnosis and treatment of cardiac conditions and cancer.

As of October 2023, Lantheus is particularly renowned for its flagship product, PyL (piflufolastat F-18), which received FDA approval for prostate cancer imaging, marking a significant advancement in the visualization of prostate-specific membrane antigen (PSMA) in patients. This product has both positioned Lantheus as a key player in the oncology space and strengthened its portfolio. Additionally, Lantheus has an extensive pipeline of other imaging agents and therapeutics targeting various diseases, underlining its commitment to advancing patient care through innovation.

The company has seen notable growth in revenue, particularly due to the commercialization of PyL, which has been well-received in the medical community. This growth reflects the increasing demand for advanced imaging technologies in oncology, giving Lantheus a competitive edge in the evolving healthcare landscape. They have also been expanding their commercial capabilities, enhancing their sales and distribution networks to maximize the reach of their products.

Lantheus Holdings Inc. operates in a dynamic market, characterized by rapid technological advancements and increasing competition. The company’s dedication to research and development, coupled with strategic partnerships and collaborations, positions it well to navigate challenges and seize opportunities in the burgeoning field of precision medicine. As such, Lantheus continues to be recognized as an influential force in the biomedical sector, poised for further growth and innovation.

MWN AI Analysis *

Lantheus Holdings Inc. (NASDAQ: LNTH) operates in the biopharmaceutical sector, specializing in diagnostic imaging and targeted therapies. The company has gained significant attention recently due to its innovative products, specifically those used in nuclear medicine for imaging and therapeutic applications. As of late 2023, Lantheus’s prospects remain strong, but potential investors should consider several factors before making any investment decisions.

Lantheus's stock performance has been bolstered by the increasing demand for its flagship product, PYLARIFY, a radiopharmaceutical used in the detection of prostate cancer. The company has also seen growth from its expanding pipeline, including PET imaging agents and therapies, which positions it well in a market with rising unmet needs. With an aging population and a growing emphasis on precision medicine, the demand for Lantheus's offerings is likely to increase.

Financial performance indicates that Lantheus has been managing its costs effectively while driving revenue growth. Analysts project continued revenue growth driven by market expansion and successful commercialization of new products. However, investors should be aware of the inherent risks in the biotech sector, including competitive pressures and regulatory hurdles that could impact product approvals and market access.

Additionally, macroeconomic conditions, such as interest rate fluctuations and broader market sentiment, could influence the stock's volatility. Given the current valuations, Lantheus may present an attractive entry point for long-term investors, provided they have a high-risk tolerance and a diversified investment strategy.

In conclusion, Lantheus Holdings Inc. could present growth opportunities in the biopharmaceutical space, but potential investors should conduct thorough due diligence and consider broader market trends before investing. Keeping a close eye on the company's clinical updates and market dynamics will be crucial to making informed decisions in the coming quarters.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Lantheus Holdings Inc. (NASDAQ:LNTH)

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.

Quote | Lantheus Holdings Inc. (NASDAQ:LNTH)

Last:$83.49
Change Percent: -0.83%
Open:$83.09
Close:$83.49
High:$85.2
Low:$82.09
Volume:733,755
Last Trade Date Time:07/09/2025 03:40:22 pm

News | Lantheus Holdings Inc. (NASDAQ:LNTH)

  • Lantheus Seems Worth The (Very Real) Risks

    2025-07-01 07:28:39 ET Lantheus Holdings ( LNTH ) appears to have a simple and compelling bull case. The flagship product, Pylarify, is a best-in-class imaging agent that should serve an (unfortunately) growing market. Definity, used to enhance echocardiograms, has a long history of...

    • July 01, 2025 07:28:39 am

    • |
    • SeekingAlpha
    • |
      • LNTH Stock
      • LNTH Quote
      • LNTH Short
      • LNTH News
      • LNTH Articles
      • LNTH Message Board
  • (LNTH) Technical Data

    2025-06-15 15:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

    • June 15, 2025 03:16:00 pm

    • |
    • Stock Traders Daily
    • |
      • LNTH Stock
      • LNTH Quote
      • LNTH Short
      • LNTH News
      • LNTH Articles
      • LNTH Message Board

Message Board Posts | Lantheus Holdings Inc. (NASDAQ:LNTH)

Subject By Source When
Interesting 8K announcing Paul Blanchfield's move to COO. Chuckles759 investorshub 06/16/2022 5:14:18 AM
I'm thinking that nothing of significance was announced/presented Chuckles759 investorshub 06/10/2022 6:38:43 PM
Any thoughts if something newsworthy will be announced Chuckles759 investorshub 06/06/2022 11:59:50 AM
$lnth covered in fake bots on this site. make it happen investorshub 05/27/2022 1:52:43 PM
Can't fault Gerald Ber for cashing in a Chuckles759 investorshub 05/13/2022 5:53:13 PM

MWN AI FAQ **

What recent advancements or innovations has Lantheus Holdings Inc. (NASDAQ: LNTH) made in the field of diagnostics and targeted therapeutics that could impact its market position?

Lantheus Holdings Inc. has made significant advancements in diagnostic imaging, particularly with its innovative PET imaging agents and targeted therapeutics, enhancing the precision of cancer detection and treatment, which could strengthen its competitive position in the healthcare market.

How has Lantheus Holdings Inc. (NASDAQ: LNTH) performed financially in the last quarter, and what factors contributed to its growth or decline during that period?

In the last quarter, Lantheus Holdings Inc. (NASDAQ: LNTH) experienced strong financial performance driven by increased sales of its nuclear medicine products and favorable pricing, despite facing challenges from supply chain constraints and competitive pressures in the industry.

What strategic partnerships or collaborations has Lantheus Holdings Inc. (NASDAQ: LNTH) established recently, and how do these align with its long-term business objectives?

Lantheus Holdings Inc. has recently established strategic partnerships with companies like GE Healthcare and recently expanded collaborations in radiopharmaceuticals, aligning with its long-term objectives to enhance imaging diagnostics and treatment options in oncology and other diseases.

How does Lantheus Holdings Inc. (NASDAQ: LNTH) plan to address potential regulatory challenges in the pharmaceutical industry moving forward?

Lantheus Holdings Inc. aims to address potential regulatory challenges by enhancing its compliance programs, engaging proactively with regulatory agencies, and investing in research and development to ensure its products meet evolving standards and requirements in the pharmaceutical industry.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get LNTH Alerts

News, Short Squeeze, Breakout and More Instantly...

Lantheus Holdings Inc. Company Name:

LNTH Stock Symbol:

NASDAQ Market:

-0.83% G/L:

$83.49 Last:

733,755 Volume:

$83.09 Open:

$83.49 Close:

Lantheus Holdings Inc. Website:

Lantheus Holdings Inc. Logo

Ad

Investor Relations
RECENT LNTH NEWS
  • LNTH - (LNTH) Technical Data

    2025-06-15 15:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

  • LNTH - Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

    BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new dat...

  • LNTH - Lantheus to Present at the 2025 Truist Securities MedTech Conference

    BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markiso...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get LNTH Alerts

Get LNTH Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1